GET DAILY SIGNALSMoleculin Biotech (MBRX) Needs +2,880% Gain to Reach $240 Central Target
Key Takeaways
- The central $240 stock price target is the arithmetic mean of three verified analyst targets — $40, $60, and $620 — not an official published consensus.
- Moleculin Biotech, Inc. (MBRX), a Phase 3 clinical-stage oncology company, last traded near $8.06, so reaching $240 would require a roughly 2,880% advance — an extraordinarily large move.
- The analyst range is very wide ($40 to $620); the $620 Roth MKM target skews the average far above the $60 median, reflecting deep disagreement over the lead drug's potential.
- All three covering analysts rate the stock a Buy, driven by positive interim Phase 3 MIRACLE data and a possible accelerated-approval pathway for Annamycin in acute myeloid leukemia.
- The strongest supports are encouraging clinical results and a differentiated safety profile; the biggest risks are recurring dilution, a limited cash runway, and no approved products yet.
- For more context on the company's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages.
- You can also follow Trending AI Robots to see which AI-driven trading strategies are gaining traction in current markets.
Breaking Down the Analyst Targets
Three sell-side analysts currently publish price targets on Moleculin Biotech, Inc. (MBRX), and all rate the shares a Buy. Jonathan Aschoff of Roth MKM carries a $620 target, Sara Nik of H.C. Wainwright carries a $60 target, and Jason McCarthy of Maxim Group carries a $40 target. The arithmetic mean of those three figures is $240, which is the central target used here. The range of $40 to $620 is unusually wide, and the median is only $60 — the $620 target is a substantial outlier that pulls the average far above the middle of the range.
This dispersion reflects genuine uncertainty about how to value a pre-revenue drug developer whose commercial future hinges on a single pivotal trial. Analysts have also been revising targets sharply lower amid heavy share issuance. The consensus rating on the stock is a Strong Buy, but that label should not be read as a guarantee: the target set implies a wide band of plausible outcomes rather than a precise forecast. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where MBRX Stands Today and the Road Ahead
With shares near $8.06 and a market capitalization of roughly $8.5 million, MBRX trades as a micro-cap after a deep decline — the stock is down about 96% over the trailing year, within a 52-week range of $3.23 to $253.05. Moving to the $240 central target would require a gain of roughly 2,880%, a very large move by any measure. Even the $40 low-end target implies an upside of about 400%.
A path toward meaningfully higher prices would depend on the company's lead drug, Annamycin (naxtarubicin), an anthracycline engineered to avoid multidrug resistance and cardiotoxicity. The pivotal MIRACLE trial is evaluating Annamycin with cytarabine in relapsed or refractory acute myeloid leukemia (AML), a blood cancer. Interim data showed a 37% blinded complete-remission rate in patients who had failed prior venetoclax therapy, with complete remission (CR) rates reported about threefold higher than the control arm. Management has described a potential accelerated-approval pathway based on the complete-remission primary endpoint.
Factors That Could Support Higher Prices
Several factors could underpin a higher valuation. The MIRACLE interim results were materially better than historical benchmarks for this difficult-to-treat population, and enrollment milestones have been met on schedule. Data presented at ASCO 2026 showed no detectable cardiotoxicity with Annamycin, a differentiating claim for an anthracycline-class drug. The company also holds patent protection in multiple jurisdictions, extending in some markets into the 2040s, and has a broader pipeline including WP1066 for brain and pancreatic tumors. If the full MIRACLE unblinding confirms the interim signal, the bull case for a substantially higher price forecast would strengthen.
Key Risks to Consider
The risks are equally concrete. Moleculin has no approved product and generates minimal revenue, so it relies on equity markets to fund operations. It has repeatedly issued new shares, including a $9.3 million public offering and additional filings to sell millions of shares, which dilutes existing holders and pressures the stock price. The company has reported GAAP (generally accepted accounting principles) EPS (earnings per share) losses that missed estimates, and its cash runway is limited. The interim data remains partially blinded, so the final results could disappoint. As a micro-cap with a beta near 2.0, the shares are also highly volatile and thinly traded.
Technical Levels and Market Structure
Technically, the stock remains in a longer-term downtrend, trading below its 50-day and 200-day simple moving averages. Near-term support sits around $7.66 to $7.89, with the 52-week low at $3.23. Resistance appears near $8.93 to $9.22, and the 200-day average, near $38.81, is a distant overhead level that would need to be reclaimed before any sustained advance could be contemplated. These levels describe market structure, not a forecast.
Time Horizon and Items to Watch
Analyst price targets generally reflect a roughly 12-month horizon, though firms do not always state a precise period. The most important upcoming items are the next earnings report, the full MIRACLE unblinding, any decision on commencing the Phase 3 portion of the trial, further data presentations, and the pace and terms of any additional financing. Regulatory feedback from the FDA will also be pivotal, as it determines whether the accelerated-approval route remains viable.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, keep an eye on existing positions, and identify changing trends more efficiently than manual screening allows. For a volatile name like MBRX, automated signals can help filter short-term noise from durable moves.
Exploring AI Tools for Research
In my own workflow, I turn to Tickeron’s AI Daily Buy/Sell Signals when evaluating names like this one. The platform scans market data in real time and flags potential shifts that might otherwise require hours of manual chart review. It has become a practical way to cross-check technical setups against broader sector moves, especially for micro-cap biotechs where liquidity and volatility can distort traditional indicators. This approach helps me stay focused on the longer-term clinical catalysts rather than day-to-day noise.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for MBRX turns negative, indicating new downward trend
MBRX saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In 78 of the 84 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MBRX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MBRX's RSI Oscillator exited the oversold zone, 44 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for MBRX just turned positive on October 23, 2026. Looking at past instances where MBRX's MACD turned positive, the stock continued to rise in 36 of 40 cases over the following month. The odds of a continued upward trend are 90%.
Following a +5.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBRX advanced for three days, in 176 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
MBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.306) is normal, around the industry mean (3.498). P/E Ratio (0.596) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. MBRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry Biotechnology
Advertisement